Clinical trial NCT05037058: China Diabetes Cardiovascular Initiative
Official title: China Diabetes Cardiovascular Initiative
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Coronary Syndrome
Diabetes Mellitus
Lead sponsor: Beijing Institute of Heart, Lung and Blood Vessel Diseases
Sponsor class: OTHER
First posted: 2021-09-08
Enrollment: 9600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients hospitalized with acute coronary syndrome and diabetes from 40 tertiary hospitals from China.

Brief summary: As a collaborative project between American Heart Association, Chinese Society of Cardiology, American Diabetes Association and Chinese Diabetes Society, the China Diabetes Cardiovascular Initiative aims to enhance the attention and awareness of cardiovascular health care professionals (HCPs) in the managements of cardiovascular diseases and diabetes, to reduce diabetes-related complication and minimize adverse events in patients with cardiovascular disease, and to reduce the risk of cardiovascular morbidity and mortality in diabetic patients.


Eligibility criteria: Inclusion Criteria:

1. Patients hospitalized with acute coronary syndrome and diabetes.
2. Aged at least 18 years.

Exclusion Criteria:

None

Primary outcomes:
measure: Proportion of patients receiving dual antiplatelet therapy at arrival (within 24 hours)
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of STEMI patients receiving fibrinolytic therapy within 30 minutes after arrival among those receiving this treatment
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of STEMI patients receiving reperfusion therapy by PCI
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of STEMI patients receiving primary PCI within 90 minutes after arrival among those receiving this treatment
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of NSTE-ACS patients receiving early cardiac troponin measurement (within 6 hours of arrival)
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of NSTE-ACS patients receiving risk stratification at admission
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of NSTE-ACS patients receiving PCI within recommended times for patients with high or intermediate risk
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of patients prescribed dual antiplatelet medications at discharge
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of patients with indications prescribed a beta-blocker at discharge
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of patients prescribed a statin at discharge
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of patients with indications prescribed an ACE-I or ARB at discharge
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of patients that receiving an LDL-C assessment
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of patients with evaluation for LV systolic function by echocardiography
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of smoking patients that receiving smoking cessation advice/counseling
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of patients receiving fasting glucose test at least twice
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of patients receiving HbA1C test
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of patients prescribed a SGLT-2 inhibitor or a GLP-1 receptor agonist at discharge with cardiovascular disease benefit
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of patients with body height and weight measured and documented
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of patients receiving guidance on individualized dietary
timeFrame: Duration of hospital stay, an expected average of 1 week
measure: Proportion of patients receiving guidance on individualized physical activity
timeFrame: Duration of hospital stay, an expected average of 1 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: